Brian Elsbernd - 03 Mar 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Compliance/Legal Officer
Signature
/s/ Brian Elsbernd
Issuer symbol
CPRX
Transactions as of
03 Mar 2025
Transactions value $
-$1,306,877
Form type
4
Filing time
05 Mar 2025, 17:00:39 UTC
Previous filing
19 Feb 2025
Next filing
05 Sep 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise $20,764 +9,270 +4.92% $2.24 197,834 03 Mar 2025 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale -$225,795 -9,720 -4.9% $23.23 188,564 03 Mar 2025 Direct F1, F2
transaction CPRX Common Stock, par value $0.001 per share Options Exercise $119,291 +53,255 +28.24% $2.24 241,819 03 Mar 2025 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale -$1,221,137 -53,255 -22.02% $22.93 188,564 03 Mar 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to Purchase Common Stock Options Exercise $0 -9,270 -0.87% $0 1,062,339 03 Mar 2025 Common Stock 9,270 $2.24 Direct F4
transaction CPRX Options to Purchase Common Stock Options Exercise $0 -53,255 -5.01% $0 1,009,084 03 Mar 2025 Common Stock 53,255 $2.24 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold for personal reasons and not as a result of a disagreement with the Company.
F2 Represents a weighted average price for the shares sold. Shares were sold in a range from $23.21 to $23.24 per share.
F3 Represents a weighted average price for the shares sold. Shares were sold in a range from $22.75 to $23.13 per share.
F4 Options vested in three annual tranches beginning on December 19, 2019.